Cyclic AMP inhibited proliferation of human aortic vascular smooth muscle cells, accompanied by induction of p53 and p21

Hypertension

Volumn 35, Issue 1 II, 2000, Pages 237-243

  Hayashi, Shin Ichiro ^a   Morishita, Ryuichi ^a   Matsushita, Hidetsugu ^a   Nakagami, Hironori ^a   Taniyama, Yoshiaki ^a   Nakamura, Toshinori ^a   Aoki, Motokuni ^a   Yamamoto, Kei ^a   Higaki, Jitsuo ^a   Ogihara, Toshio ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

Apoptosis; Atherosclerosis; Cyclic AMP; Remodeling; Restenosis

Indexed keywords

8 BROMO CYCLIC AMP; CILOSTAZOL; CYCLIC AMP; DNA FRAGMENT; FORSKOLIN; PHOSPHODIESTERASE INHIBITOR; PROTEIN P21; PROTEIN P53; RECOMBINANT PLATELET DERIVED GROWTH FACTOR;

AORTA MEDIA; APOPTOSIS; CELL CYCLE; CELL GROWTH; CELL PROLIFERATION; CONFERENCE PAPER; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN INDUCTION; SECOND MESSENGER; VASCULAR SMOOTH MUSCLE;

EID: 0033977303     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.hyp.35.1.237     Document Type: Conference Paper

References (46)

1. Beavo JA, Conti M, Heaslip RJ. Multiple cyclic nucleotide phosphodiesterases. Mol Pharmacol 1994;46:399-405.
2. Tani T, Sakurai K, Kimura Y, Ishikawa T, Hidaka H. Pharmacological manipulation of tissue cyclic AMP by inhibitors: effects of phosphodiesterase inhibitors on the functions of platelets and vascular endothelial cells. Adv Second Messenger Phosphoprotein Res. 1992;25: 215-227.
3. Tanaka T, Ishikawa T, Hagiwara M, Onoda K, Itoh H, Hidaka H. Effects of cilostazol, a selective cAMP phosphodiesterase inhibitor, on the contraction of vascular smooth muscle. Pharmacology. 1988;36:313-320.
4. Dawson DL, Cutler BS, Meissner MH, Strandness DE. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation. 1998;98:678-686.
5. Tanaka K, Gotoh F, Fukuuchi Y, Amano T, Uematsu D, Kawamura J, Yamawaki T, Itoh N, Obara K, Muramatsu K. Effects of a selective inhibitor of cyclic AMP phosphodiesterase on the pial microcirculation in feline cerebral ischemia. Stroke. 1989;20:668-673.
6. Fujitani K, Kambayashi J, Murata K, Yano Y, Shiozaki K, Yukawa M, Sakon M, Murata T, Kawasaki T, Shiba E, Mori T. Clinical evaluation of combined administration of oral prostacyclin analogue beraprost and phosphodiesterase inhibitor cilostazol. Pharmacol Res. 1995;31: 121-125.
7. Souness JE, Hassall GA, Parrott DP. Inhibition of pig aortic smooth muscle cell DNA synthesis by selective type III and type IV cyclic AMP phosphodiesterase inhibitors. Biochem Pharmacol. 1992;44:857-866.
8. Koh E, Morimoto S, Jiang B, Inoue T, Nabata T, Kitano S, Yasuda O, Fukuo K, Ogihara T. Effects of beraprost sodium, a stable analogue of prostacyclin, on hyperplasia, hypertrophy and glycosaminoglycan synthesis of rat aortic smooth muscle cells. Artery. 1993;20:242-252.
9. 1 inhibits DNA synthesis in arterial smooth muscle cells stimulated with platelet-derived growth factor. Atherosclerosis. 1984;53:77.
10. Bornfeldt KE, Graves LM, Raines EW, Igarashi Y, Wayman G, Yamamura S, Yatomi Y, Sidhu JS, Krebs EG, Hakomori S, et al. Sphingosine-1-phosphate inhibits PDGF-induced chemotaxis of human arterial smooth muscle cells: spatial and temporal modulation of PDGF chemotactic signal transduction. J Cell Biol. 1995;130:193-206.
11. Meinkoth JL, Montminy MR, Fink JS, Feramisco JR. Induction of a cyclic AMP-responsive gene in living cells requires the nuclear factor CREB. Mol Cell Biol. 1991;11:1759-1764.
12. Indolfi C, Avvedimento EV, Di Lorenzo E, Esposito G, Rapacciuolo A, Giuliano P, Grieco D, Cavuto L, Stingone AM, Ciullo I, Condorelli G, Chiariello M. Activation of cAMP-PKA signaling in vivo inhibits smooth muscle cell proliferation induced by vascular injury. Nat Med. 1997;3: 775-779.
13. Tsuchikane E, Fukuhara A, Kobayashi T, Kirino M, Yamasaki K, Kobayashi T, Izumi M, Otsuji S, Tateyama H, Sakurai M, Awata N, Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty. Circulation. 1999;100:21-26.
14. Take S, Matsutani M, Ueda H, Hamaguchi H, Konishi H, Baba Y, Kawaratani H, Sugiura T, Iwasaka T, Inada M. Effect of cilostazol in preventing restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol. 1997;79:1097-1099.
15. Bonin PD, Leadley RJ, Erickson LA. Growth factor-induced modulation of endothelial-1 binding to human smooth muscle cells. J Cardiovasc Pharmacol. 1993;22:S125-S127.
16. Libby P, O'Brien KV. Culture of quiescent arterial smooth muscle cells in a defined serum-free medium. J Cell Physiol. 1983;115:217-223.
17. Ishiyama M, Shiga M, Sasamoto K, Mizoguchi M, He P. A new sulfonated tetrazolium salt that produces a highly water-soluble formazan dye. Chem Pharm Bull (Tokyo). 1993;41:1118-1122.
18. Aoki M, Morishita R, Matsushita H, Nakano N, Hayashi S, Tomita N, Yamamoto K, Moriguchi A, Higaki J, Ogihara T. Serum deprivation induced apoptosis accompanied by up-regulation of p53 and bax in human aortic vascular smooth muscle cells. Heart Vessels. 1997;S12: 71-75.
19. Aoki M, Morishita R, Matsushita H, Hayashi S, Nakagami H, Yamamoto K, Moriguchi A, Kaneda Y, Higaki J, Ogihara T. Inhibition of the p53 tumor suppressor gene results in growth of human aortic vascular smooth muscle cells: potential role of p53 in regulation of vascular smooth muscle cell growth. Hypertension. 1999;34:192-200.
20. Ito M, Watanabe M, Ihara T, Kamiya H, Sakurai M. Fas antigen and bcl-2 expression on lymphocytes cultured with cytomegalovirus and varicellazoster virus antigen. Cell Immunol. 1995;160:173-177.
21. Morishita R, Gibbons GH, Ellison KE, Nakajima M, Zhang L. Kaneda Y, Ogihara T, Dzau VJ. Single intraluminal delivery of antisense cdc 2 kinase and PCNA oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc Natl Acad Sci U S A. 1993;90: 8474-8478.
22. Morishita R, Gibbons GH, Ellison KE, Nakajima M, Leyen HVL, Zhang L, Kaneda Y, Ogihara T, Dzau VJ. Intimai hyperplasia after vascular injury is inhibited by antisense cdk 2 kinase oligonucleotides. J Clin Invest. 1994;93:1458-1464.
23. Morishita R, Gibbons GH, Horiuchi M, Ellison KE, Nakajima M, Zhang L, Kaneda Y, Ogihara T, Dzau VJ. A novel molecular strategy using cis element 'decoy' of E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci U S A. 1995;92:5855-5859.
24. Chang MW, Barr E, Seltzer J, Jiang YQ, Nabel GJ, Nabel EG, Parmacek MS, Leiden JM. Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science. 1995;267:518-522.
25. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzeler KW, Vogelstein B. WAF 1, a potential mediator of p53 tumor suppression. Cell. 1993;75:817-825.
26. Harper JW, Adami GR, Wei N, Keyomarski K, Elledge SJ. The p21 CDK-interacting protein Cip 1 is a potential inhibitor of G1 cyclin-dependent kinases. Cell. 1993;75:805-816.
27. Symonds H, Krall L, Remington L, Saenz-Robles M, Lowe S, Jacks T, Dyke TV. p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell. 1994;78:703-711.
28. Shaw P, Bovey R, Tardy S, Sahli R, Sordat B, Costa J. Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc Natl Acad Sci USA. 1992;89:4495-4499.
29. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature. 1991;352:345-347.
30. Brown SL, Lundgren CH, Nordt T, Fujii S. Stimulation of migration of human aortic smooth muscle cells by vitronectin: implications for atherosclerosis. Cardiovasc Res. 1994;28:1815-1820.
31. Koyama N, Morisaki N, Saito Y, Yoshida S. Regulatory effects of platelet-derived growth factor-AA homodimer on migration of vascular smooth muscle cells. J Biol Chem. 1992;267:22806-22812.
32. Horio T, Kohno M, Kano H, Ikeda M, Yasunari K, Yokokawa K, Minami M, Takeda T. Adrenomedullin as a novel antimigration factor of vascular smooth muscle cells. Circ Res. 1995;77:660-664.
33. Lampugnani MG, Giorgi M, Gaboli M, Dejana E, Marchisio PC. Endothelial cell motility, integrin receptor clustering, and microfilament organization are inhibited by agents that increase intracellular cAMP. Lab Invest. 1990;63:521-531.
34. De Cesare D, Fimia GM, Sassone-Corsi P. Signaling routes to CREM and CREB: plasticity in transcriptional activation. Trends Biochem Sci. 1999; 24:281-285.
35. Vogelstein B, Kinzler KW. P53 function and dysfunction. Cell. 1992;70: 523-526.
36. Lane DP. p53: guardian of the genome. Nature. 1992;258:15-16.
37. Miyashita T, Harigai M, Hanada M, Reed JC. Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res. 1994;54:3131-3135.
38. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell. 1995;80:293-299.
39. Bai HZ, Morishita R, Kida I, Yamakawa T, Zhang WD, Aoki M, Matsushita H, Noda A, Nagai R, Kaneda Y, Higaki J, Ogihara T, Sawa Y, Matsuda H. Inhibition of intimai hyperplasia after vein grafting by in vivo transfer of human senescent cell-derived inhibitor-1 gene. Gene Ther. 1998;5:761-769.
40. Speir E, Modali R, Huang ES, Leon MB, Shawl F, Finkel T, Epstein SE. Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science. 1994;265:391-394.
41. Tsai HL, Kou GH, Chen SC, Wu CW, Lin YS. Human cytomegalovirus immediate-early protein IE2 tethers a transcriptional repression domain to p53. J Biol Chem. 1996;271:3534-3540.
42. Amsterdam A, Keren-Tal I, Aharoni D. Cross-talk between cAMP and p53-generated signals in induction of differentiation and apoptosis in steroidogenic granulosa cells. Steroids. 1996;61:252-256.
43. Matsushita H, Morishita R, Kida I, Aoki M, Hayashi S, Tomita N, Yamamoto K, Moriguchi A, Noda A, Kaneda Y, Higaki J, Ogihara T. Inhibition of growth of human vascular smooth muscle cells by over-expression of p21 gene through induction of apoptosis. Hypertension. 1998;31:493-498.
44. Isner JM, Kearney M, Bortman S, Passeri J. Apoptosis in human athero-sclerosis and restenosis. Circulation. 1995;91:2703-2711.
45. Aharoni D, Dantes A, Oren M, Amsterdam A. cAMP-mediated signals as determinants for apoptosis in primary granulosa cells. Exp Cell Res. 1995;218:271-282.
46. Duprez E, Gjertsen BT, Bernard O, Lanotte M, Doskeland SO. Antiapoptotic effect of heterozygously expressed mutant RI (Ala336→Asp) subunit of cAMP kinase I in a rat leukemia cell line. J Biol Chem. 1993;268:8332-8340.